Cloxamp DC 600

Intramammary preparation

This product is indicated for the treatment of dairy cows at drying off only, that is immediately after the last milking of the lactation. To treat existing mastitis caused by, or associated with, organisms sensitive to cloxacillin and ampicillin. To provide prolonged protection against further infections during the dry period.

Read the entire label prior to use. Taking antiseptic precautions, introduce contents of one injector into each quarter via the teat canal. Treat after the final milking of the lactation, and at least 49 days before calving. The variable tip allows for either full or partial insertion into the teat orifice. Partial insertion only is preferable, as it may prevent unnecessary damage to the teat orifice and reduce the risk of infection. Full insertion will be needed for large teat orifices

It is an offence for users of this product to cause residues exceeding the relevant MRL in the Food Notice: Maximum Residue Levels for Agricultural Compounds.

MILK: Milk (colostrum) from the first 8 milkings after calving should be prevented from directly entering the human food chain. Should a cow (which has been treated at drying off) calve earlier than 49 days after treatment, milk must be withheld for 49 days after the last treatment ensuring that milk from the first 8 milkings is withheld.

MEAT: Animals producing meat or offal for human consumption must not be sold for slaughter either during treatment or within 30 days of the last treatment.

Bobby calves: Meat: When a cow calves within the 30 day meat withholding period, the calf must be withheld from slaughter for 7 days on clean milk following consumption of colostrum from that cow.

Milk: Milk from the first 8 milkings can be fed to bobby calves if the cow calves outside the 49 day treatment to calving interval.

Ampicillin and cloxacillin are antibiotics in the penicillin family and are considered Highly Important to human and animal health. The use of these antibiotics should only be for the minimum period needed to meet the clinical objective. Clinical response to these antibiotics should be monitored during treatment, and choice of therapy reviewed if clinical signs of disease persist, increase, or relapse. In the event of treatment failure, culture and sensitivity should be considered to determine an appropriate alternative therapy. Indiscriminate use of these antibiotics can contribute to the development of antibiotic resistance.